Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • CORRESPONDENCE

Forget lung, breast or prostate cancer? Why we shouldn’t abandon tumour names yet

  1. Albrecht Stenzinger

    1. University Hospital Heidelberg, Heidelberg, Germany.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  2. Frederick Klauschen

    1. Ludwig-Maximilians-Universität München, Munich, Germany.

    View author publications

    You can also search for this author in PubMed  Google Scholar

André et al. argue that classifying cancer solely on the basis of organ origin imperfectly informs tumour biology, and should be replaced by molecular profiling of tumour cells regardless of tissue type (Nature 626, 26–29; 2024). They reason that many therapies have shown efficacy across different cancers, and that clinical trials involving people with various cancers could accelerate drug development.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature 627, 38 (2024)

doi: https://doi.org/10.1038/d41586-024-00632-5

Competing Interests

A.S. is on the advisory board or speaker’s bureau for Aignostics, Amgen, Astellas, Astra Zeneca, Bayer, BMS, Eli Lilly, Illumina, Incyte, Janssen, MSD, Novartis, Pfizer, Qlucore, QuiP, Roche, Sanofi, Seagen, Servier, Takeda and Thermo Fisher, and has research grants from Bayer, BMS, Chugai and Incyte. F.K. is co-founder of Aignostics and is on the advisory board or speaker’s bureau for Agilent, Aignostics, Astra Zeneca, BMS, Illumina, Merck, MSD, Pfizer, Roche and Sanofi.

Subjects

Latest on:

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links